Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR

SAFE-HEART is a single-centre, randomized controlled trial comparing the safety and efficiency of Apixaban versus Warfarin in the early period (3 months) after repair or bioprosthetics of the mitral and aortic valve cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.

NCT Number	NCT07434661
Lead Sponsor	Meshalkin Research Institute of Pathology of Circulation
Conditions	Valve Disease, Heart, Atrial Fibrillation (AF), Valve Replacement Surgery, Aortic Valve Surgery, Mitral Valve Annuloplasty, Mitral Valve Repair, Mitral Valve Surgery
Enrollment	120 participants
Start Date	2026-02
Primary Completion	2028-01 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-25